ESR1 and breast carcinoma: Anti-estrogen therapy targeting the estrogen-mediated signaling pathway is an essential component of treatment for both early and advanced-stage breast cancer expressing the estrogen receptor (ER) and/or progesterone receptor (PR)1,2.